Holen Sie sich die Stockscreener-App
3.73
1.44%
-0.10
Schlusskurs vom Vortag:
$3.83
Offen:
$3.79
24-Stunden-Volumen:
13,906
Relative Volume:
0.11
Marktkapitalisierung:
$4.93M
Einnahmen:
$10.48M
Nettoeinkommen (Verlust:
$-37.74M
KGV:
-0.2305
EPS:
-16.1846
Netto-Cashflow:
$-29.03M
1W Leistung:
-7.02%
1M Leistung:
-42.80%
6M Leistung:
-84.42%
1J Leistung:
-95.93%
1-Tages-Spanne:
$3.755
$3.83
1-Wochen-Bereich:
$3.71
$4.0706
52-Wochen-Spanne:
$3.71
$110.75
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Vergleichen Sie JAGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.755 | 4.93M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.92 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.39 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
303.69 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
580.50 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
271.82 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - The Oklahoman
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Cani - GuruFocus
Jaguar Health Establishes First Site for Canalevia-CA1 Field Study - marketscreener.com
First Study Site Established for Jaguar Health Study of its FDA - GuruFocus
Jaguar Health (JAGX) Advances Canalevia-CA1 Field Study for Canine Treatment | JAGX Stock News - GuruFocus
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | JAGX Stock News - GuruFocus
First FDA-Approved Dog Diarrhea Treatment Targets 6M Annual Cases with New Clinical Study - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Call Transcript - MSN
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - The Oklahoman
Jaguar Health Reports First Quarter 2025 Financials - The Columbus Dispatch
Jaguar Health Provides Update on Meeting with FDA Discussing Sta - GuruFocus
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer By Investing.com - Investing.com South Africa
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Akron Beacon Journal
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health to Reveal Critical FDA Feedback on Breakthrough Phase 3 Breast Cancer Trial Results - Stock Titan
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | - GuruFocus
Jaguar Health (JAGX) Advances Plans for Crofelemer Application | JAGX Stock News - GuruFocus
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - The Columbus Dispatch
Jaguar Health Eyes FDA Orphan Drug Designation for Crofelemer - Investing.com
Breakthrough: FDA Meeting Could Fast-Track New Breast Cancer Treatment Following Positive Trial Data - Stock Titan
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates - ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series - Detroit Free Press
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series | JAGX Stock News - GuruFocus
Jaguar Health CEO to Reveal New Orphan Drug Development Strategy: Key Updates Coming June 10 - Stock Titan
Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th - ACCESS Newswire
Knight Therapeutics and Jaguar Health Announce Strategic Partnership - ACCESS Newswire
Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - The Columbus Dispatch
Jaguar Health (NASDAQ:JAGX) Upgraded at Wall Street Zen - Defense World
Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer - ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ - MSN
Jaguar Health Announces $1.5M Direct Stock Offering - TipRanks
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering - MSN
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’ By Stocktwits - Investing.com India
Jaguar Health announces $1.5 million direct offering By Investing.com - Investing.com South Africa
Jaguar Health (JAGX) Announces Direct Offering and Private Placement | JAGX Stock News - GuruFocus
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):